Welcome to our dedicated page for Cyclerion Therapeutics news (Ticker: CYCN), a resource for investors and traders seeking the latest updates and insights on Cyclerion Therapeutics stock.
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing treatments for serious and orphan diseases. Established in 2018 and headquartered in Cambridge, Massachusetts, Cyclerion harnesses the potential of soluble guanylate cyclase (sGC) pharmacology to create groundbreaking therapies for conditions with significant unmet medical needs.
The company's portfolio includes several promising product candidates:
- Olinciguat: An orally administered vascular sGC stimulator currently in Phase II studies aimed at treating sickle cell disease (SCD).
- Praliciguat: An orally administered systemic sGC stimulator in Phase II trials targeting diabetic nephropathy and heart failure with preserved ejection fraction.
- IW-6463: An orally administered, CNS-penetrant sGC stimulator in Phase I trials for neurodegenerative diseases.
In addition to these advanced candidates, Cyclerion is also working on discovering liver-targeted and lung-targeted sGC stimulators.
One of the latest developments for Cyclerion is its strategic partnership with Tisento Therapeutics, Inc. In July 2023, Cyclerion announced the closing of an asset purchase agreement with Tisento, which includes an $81 million Series A financing to support the development of Phase 2 soluble guanylate cyclase (sGC) stimulator zagociguat and other assets. Cyclerion received 10 percent equity ownership in Tisento, providing its shareholders with future value creation opportunities.
Cyclerion’s collaboration with Tisento marks a significant advancement, particularly for the brain-penetrant sGC stimulators zagociguat and CY3018. Phase 2a data from Cyclerion's studies demonstrated that zagociguat could significantly improve disease-associated biomarkers in patients with MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes), offering hope for better treatment options where none previously existed.
With a focus on delivering new therapeutic solutions, Cyclerion continues to explore collaborations, licenses, and other strategic options to enhance shareholder value while advancing its portfolio of innovative treatments.
Cyclerion Therapeutics announces participation in the Annual Biomarkers for Alzheimer's Disease Summit on August 25-26, 2021. Presenters include Chris Winrow, Ph.D., discussing early clinical assessment of biomarkers for Alzheimer’s therapies, and Juli Jones, Ph.D., focused on omics platforms in drug discovery. Key presentations occur on August 25 at 4:20 p.m. ET and August 26 at 2:30 p.m. ET, followed by a Q&A. Cyclerion is advancing CY6463, targeting cognitive function restoration in diseases like Alzheimer's and schizophrenia.
Cyclerion Therapeutics reported significant advancements in clinical development for CY6463, a CNS-penetrant sGC stimulator, targeting Alzheimer's disease with vascular pathology (ADv) and related conditions. The FDA approved the IND application for CY6463, initiating a 12-week Phase 2a trial in ADv. Cyclerion raised approximately $30.5 million through private placements and an ATM offering in Q2 2021. The net loss decreased to $16.2 million from $19.5 million year-over-year. The company is also progressing CY3018 and has partnerships aimed at enhancing clinical developments.
Cyclerion Therapeutics (Nasdaq: CYCN) is set to present its Phase 2a study design for its lead candidate, CY6463, targeting Alzheimer’s disease with vascular pathology at the Alzheimer’s Association International Conference 2021, occurring from July 26-30, 2021. The research showcases neuropsychological biomarkers as predictors of cognitive performance in Alzheimer's patients. Cyclerion's innovative approach aims to restore cognitive function, as the company continues to advance treatments for various CNS disorders, with CY6463 demonstrating promise in earlier studies.
Cyclerion Therapeutics (Nasdaq: CYCN) and Beacon Biosignals have expanded their strategic partnership to enhance the development of Cyclerion's therapeutics targeting neurological diseases linked to cognitive impairment. Utilizing Beacon's EEG neurobiomarker platform, the collaboration aims to identify biomarkers for better patient selection and clinical endpoints. Cyclerion’s lead candidate, CY6463, has shown promising impacts on EEG parameters and is being evaluated in various ongoing studies, including those for Alzheimer's disease and schizophrenia.
Cyclerion Therapeutics (Nasdaq: CYCN) has announced an expanded strategic partnership with Beacon Biosignals to enhance data collection and analytics for developing investigational therapeutics targeting neurological diseases linked to cognitive impairment. This collaboration aims to identify relevant biomarkers and improve patient selection for Cyclerion's clinical studies, including those for CY6463, a CNS-penetrant sGC stimulator. Ongoing studies focus on conditions like Alzheimer’s with vascular pathology and cognitive impairment associated with schizophrenia.
Cyclerion Therapeutics has entered a global licensing agreement with Akebia Therapeutics for the development of praliciguat, a treatment for kidney disease. Cyclerion is set to receive up to $585 million in potential milestone payments and tiered royalties. This deal allows Cyclerion to concentrate on its key projects, CY6463 and CY3018, which target cognitive impairment. The agreement positions Cyclerion to benefit from Akebia's expertise in kidney disease, enhancing its strategic focus on developing CNS therapies.
Cyclerion Therapeutics announced a private sale of approximately $18 million in common stock to several notable investors, aimed at funding the clinical development of CY6463 and advancing the CY3018 program. The private placement involves selling 5,735,988 shares at $3.12 per share.
CEO Peter Hecht emphasized the capital will accelerate studies for CY6463, targeting cognitive impairment linked to various neurological diseases. The company plans to register the securities with the SEC within 10 business days.
Cyclerion Therapeutics (CYCN) announced the publication of preclinical data on CY6463, a first-in-class, CNS-penetrant sGC stimulator aimed at treating neurological diseases tied to cognitive impairment, including Alzheimer's disease with vascular pathology. The studies demonstrated that CY6463 improves neuronal function and cognitive performance while showing favorable safety and tolerability in initial clinical studies. Cyclerion is advancing a Phase 2 study of CY6463 in MELAS patients and plans further studies in Alzheimer's and Schizophrenia-related cognitive impairment.
Cyclerion Therapeutics announced that its management will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 4:00 p.m. ET. Investors can request individual meetings through Jefferies. The presentation will be accessible via the Investors & Media section of the Cyclerion website, and an archived replay will be available for 90 days post-event.
Cyclerion is focused on developing treatments to restore cognitive function, with its lead compound CY6463 currently in clinical trials for Alzheimer's Disease and other cognitive impairments.
Cyclerion Therapeutics has made significant strides in its development strategies for CY6463, a CNS-penetrant sGC stimulator, receiving FDA IND clearance for Alzheimer's Disease with vascular pathology (ADv) and advancing its MELAS program. The company plans to initiate a clinical trial for ADv by mid-2021. Additionally, a new clinical program for cognitive impairment associated with schizophrenia (CIAS) was introduced with insights from Dr. Andreas Reif. Cyclerion also announced CY3018, a next-generation sGC stimulator, aiming to enhance CNS treatment.
FAQ
What is the current stock price of Cyclerion Therapeutics (CYCN)?
What is the market cap of Cyclerion Therapeutics (CYCN)?
What does Cyclerion Therapeutics, Inc. specialize in?
What are some of the key products in Cyclerion’s pipeline?
What recent partnership did Cyclerion enter?
What is zagociguat?
Where is Cyclerion Therapeutics headquartered?
What are the financial benefits of Cyclerion’s deal with Tisento?
Who are the major investors in Tisento’s Series A financing?
What is the focus of Cyclerion’s research and development?
What distinguishes Cyclerion’s approach to drug development?
How can investors and media contact Cyclerion?
